Catalina Capital Group LLC Takes $208,000 Position in West Pharmaceutical Services, Inc. (NYSE:WST)

Catalina Capital Group LLC acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 525 shares of the medical instruments supplier’s stock, valued at approximately $208,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Fidelis Capital Partners LLC acquired a new position in shares of West Pharmaceutical Services in the 1st quarter valued at approximately $27,000. Quarry LP raised its position in shares of West Pharmaceutical Services by 155.3% in the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares in the last quarter. Planned Solutions Inc. acquired a new position in shares of West Pharmaceutical Services in the 4th quarter valued at approximately $39,000. Hazlett Burt & Watson Inc. acquired a new position in shares of West Pharmaceutical Services in the 1st quarter valued at approximately $40,000. Finally, Northwest Investment Counselors LLC acquired a new position in shares of West Pharmaceutical Services in the 1st quarter valued at approximately $40,000. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the completion of the sale, the senior vice president now owns 2,860 shares of the company’s stock, valued at approximately $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Stock Performance

Shares of NYSE WST traded up $9.41 during trading on Thursday, reaching $330.76. The stock had a trading volume of 141,424 shares, compared to its average volume of 531,255. West Pharmaceutical Services, Inc. has a one year low of $310.00 and a one year high of $415.73. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. The stock has a market cap of $24.09 billion, a PE ratio of 42.39, a P/E/G ratio of 5.65 and a beta of 1.00. The firm’s 50 day moving average price is $335.13 and its two-hundred day moving average price is $358.65.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.27. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The business had revenue of $695.40 million during the quarter, compared to the consensus estimate of $670.62 million. During the same period in the previous year, the business earned $1.98 EPS. The business’s quarterly revenue was down 3.0% on a year-over-year basis. On average, research analysts forecast that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 31st will be paid a dividend of $0.20 per share. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a yield of 0.24%. West Pharmaceutical Services’s payout ratio is currently 10.55%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.